Document is current

Article History

Received: 5 September 2025

Accepted: 23 September 2025

First Online: 17 December 2025

Competing interests

: R.B.Z. receives research funding from Janssen Inc. He has received speaking fees from Janssen Inc. and consulting fees from Boehringer Ingelheim. O.A. has served on Advisory Boards and has been a consultant to: Janssen-Ortho (Johnson & Johnson); Otsuka; Lundbeck; Allergan/Abbvie; Mylan/Viatris; Teva; Newron. Dr. Agid has received speaking fees from: Janssen-Ortho (Johnson & Johnson); Lundbeck, Otsuka, Mylan/Viatris, HLS Therapeutics; Allergan/Abbvie; O.A. has received research support from: Janssen-Ortho (Johnson & Johnson); Lundbeck; Otsuka; Boehringer Ingelheim; G.R. receives research support from the Canadian Institutes of Health Research (CIHR), University of Toronto, and HLS Therapeutics Inc.